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Hemolytic uremic syndrome (HUS) is a
thrombotic microangiopathy character-
ized by intravascular hemolysis, throm-
bocytopenia, and acute kidney failure. HUS
is usually categorized as typical, caused
by Shiga toxin–producing Escherichia coli
(STEC) infection, as atypical HUS (aHUS),
usually caused by uncontrolled comple-
ment activation, or as secondary HUS with
a coexisting disease. In recent years, a
general understanding of the pathogenetic
mechanisms driving HUS has increased.
Typical HUS (ie, STEC-HUS) follows a
gastrointestinal infection with STEC,
whereas aHUS is associated primarily
withmutationsor autoantibodies leading
to dysregulated complement activation.
Among the 30% to 50% of patients with
HUS who have no detectable complement
defect, some have either impaired diac-
ylglycerol kinase « (DGK«) activity, co-
balamin C deficiency, or plasminogen
deficiency. Some have secondary HUS
with a coexisting disease or trigger such
as autoimmunity, transplantation, can-
cer, infection, certain cytotoxic drugs, or
pregnancy. The common pathogenetic
features in STEC-HUS, aHUS, and sec-
ondary HUS are simultaneous damage to
endothelial cells, intravascular hemoly-
sis, and activation of platelets leading
to a procoagulative state, formation of
microthrombi, and tissue damage. In this
review, the differences and similarities in
the pathogenesis of STEC-HUS, aHUS, and
secondaryHUSarediscussed.Common for
the pathogenesis seems to be the vicious
cycle of complement activation, endothelial
cell damage, platelet activation, and throm-
bosis. This process can be stopped by
therapeutic complement inhibition in most
patients with aHUS, but usually not those
with a DGK« mutation, and some patients
with STEC-HUS or secondary HUS. There-
fore, understanding the pathogenesis of
the different forms of HUS may prove
helpful in clinical practice. (Blood. 2017;
129(21):2847-2856)
Introduction
Hemolytic uremic syndrome (HUS) is one of the disease processes
that belong to thrombotic microangiopathies (TMAs). The common
features forTMAsaremicroangiopathic hemolysis, thrombocytopenia,
and thrombi in small vessels that lead to end organ damage. The most
frequently encounteredTMAsclinically areHUSassociatedwithShiga
toxin–producing Escherichia coli infection (STEC-HUS) and throm-
botic thrombocytopenic purpura (TTP), followed by atypical HUS
(aHUS) and HUS with a coexisting disease (called secondary HUS).1
TMAsare alsopart of thepathologyof other conditions suchas elevated
hemolysis and liver enzymes and low platelet count (collectively called
HELLP syndrome),2 disseminated intravascular coagulation,3 malig-
nant hypertension,4 antiphospholipid antibody syndrome,5 and sclero-
derma renal crisis.6
Within the TMA syndromes, knowledge regarding the pathogen-
esis of STEC-HUS and aHUS has recently increased considerably.
STEC-HUS is usually initiated a few days after clinical gastroenteritis
caused by STEC (usually serotype O157:H7 or O104:H4), and the
Shiga toxin is central in causing endothelial cell damage, thereby
apparently initiating the disease process. Understanding the central
differences in pathogenesisbetween aHUSandSTEC-HUSbeganwith
the discovery of the association between aHUS and mutations in the
gene coding for the key complement regulator in plasma, complement
factor H (CFH).7 Thereafter, mutations in several other complement
regulators andother complement proteins, such asC3, factorB, factor I,
and CD46, have been identiﬁed.8 Many patients have more than
1 mutation or rare polymorphisms affecting the complement system.9
In addition tomutations in complement proteins, somepatientswith
aHUS have mutations also in or only in molecules not directly linked
to the complement system. Those molecules include diacylglycerol
kinasee,10 plasminogen,11 and factorXII (althoughonly in thepresence
of anti-factor H autoantibodies).9,12 In addition, some patients with
aHUS are associated with mutations in thrombomodulin (CD141),13
which has a role in both coagulation and complement regulation.13,14
In secondary HUS, a coexisting disease such as autoimmunity,
transplantation, or cancer, or an infection, normal pregnancy, or use of
certain cytotoxic drugs is associated with disease manifestation.15
Pathogenesis of secondary HUS has not been intensively studied, but
complement is involved in some cases. In this review, the pathogenesis
of STEC-HUS, aHUS, and secondary HUS are discussed with an
emphasis on the role of complement in the disease processes and the
similarities and differences between STEC-HUS and aHUS, also
considering the possible role of complement in secondary HUS.
Initiation of disease processes in HUS
STEC-HUS
The process of pathogenesis in typical HUS or STEC-HUS is
apparently initiated when the Shiga toxin (or Shiga-like toxin), a
known potent cytotoxin, binds to cell membrane glycolipid Gb3 (via
domain B). Domain A is internalized and subsequently halts protein
synthesis and induces apoptosis of the affected cell.16 The Shiga toxin
has several additional effects on endothelial cells, one of which is
enhanced expression of functional tissue factor that could contribute to
microvascular thrombosis.17 The toxin causes damage to or activation
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of endothelium,18 red cells,19 and platelets.20 Clinically, STEC-HUS
can be nearly as severe as aHUS (with mortality of up to 5%), as ex-
empliﬁed during the wide outbreak in Germany and some other
European countries in 2011.21 The main reason why gastrointestinal
infection particularly affects kidneys is thought to be the tissue tropism
of Shiga-toxin on the basis of the strong expression of Gb3 on the
glomerular endothelium.22
Secondary HUS
Secondary HUS is initiated by a coexisting disease or condition.
The most frequently reported diseases that lead to clinically evident
secondary HUS include infections, especially those caused by
Streptococcus pneumoniae,23 and the inﬂuenza virus.24 These infec-
tions are considered as causes of HUS not just triggers for the disease,
although the distinction between cause and trigger is not evident. In
addition to infections, secondary HUS may be associated with trans-
plantation (solid organ or bone marrow),25-28 autoimmune disease,29,30
cancer,31,32 pregnancy,33 and the use of certain cytotoxic drugs.34,35 The
common feature for these coexisting diseases or conditions is that they
may cause direct cell damage, promote activation of the complement
system in general, or enhance activation of complement on self cells
(Figure 1).
aHUS
According to the currently prevailing classiﬁcation, aHUS is not
associatedwith infections or a coexisting disease.15 Instead, it is usually
associated with a genetic or acquired defect in regulation of com-
plement activation on host cells. In a number of aHUS patients, an
infection (often an upper respiratory tract infection) precedes the
clinical triad typical for TMAs.8 In aHUS, infections are usually
considered as triggers, not as causes of the disease as such.
Common features
The symptoms and clinical signs may be practically identical in
STEC-HUS, secondary HUS, and aHUS. Another common feature is
that some patients with aHUS and also STEC-HUS and secondary
HUS have either mutations or autoantibodies that are associated with
impaired complement regulation.19,36-38 It is also noteworthy that
the same set of cells (endothelial cells, red cells, and platelets) may
be damaged or activated in both STEC-HUS39 and aHUS,40,41 and
apparently in secondary HUS as well. These common features indicate
similarities in disease pathogenesis of these 3 forms of HUS.
Complement as a danger for plasma-exposed
cells
Complement as an immune defense
Complement is activatedvia3pathways: classical, lectin, andalternative.
All the pathways lead to target elimination via 2 main mechanisms,
which are phagocytosis and direct lysis. The more important of these
is promotion of phagocytosis via opsonization with C3b and its
fragments, as well as phagocyte attraction via release of powerful
chemotactic and anaphylatoxic peptides such as C5a.42 These
phenomena lead to rapid opsonophagocytosis of the target by
neutrophils and macrophages (Figure 2A). The second main mech-
anism of target elimination by complement is direct lysis of target
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Figure 1. Predisposing factors, promoters, and triggers of aHUS and secondary HUS. Under physiological conditions, regulation of complement is always at a higher
level than the activation challenge. (Right) Regulation consists of the role of the membrane regulators CD35, CD46, CD55, and CD59, and the plasma regulators factors H and
I. Regulation is compromised by mutations in complement regulators, autoantibodies against factor H, or potentially some infections in which microbes remove sialic acids
from the surface of self cells. Regulation is enhanced by upregulation of complement protein expression in liver (eg, because of acute phase reaction or pregnancy) or
introduction of additional regulators by plasma exchange. (Left) Activation of complement consists of continuous alternative pathway activation and occasional (or longer
standing) physiological or pathological activation. The level of complement activation can be increased by mutations in complement proteins C3 or factor B, infections,
iatrogenic phenomena (eg, transplantation, plasma exchange, or certain drugs), pregnancy, or malignancy. The net result of all the activation and regulation boosting or
inhibiting effects may dictate whether activation overrides regulation leading or contributing to a pathological process.
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cells via formation ofmembrane pores, or so-calledmembrane attack
complexes (Figure 2A).43,44 In addition to these effects, complement
also has a role in initiating and enhancing the adaptive immunity.45
Activation of complement
Most immune systems recognize targets by self molecules that bind to
pathogen-associated molecular patterns (cellular immunity) or mole-
cules speciﬁc to a certainmicrobe (antibody-mediated immunity). This
is also true for the classical pathway of complement, which recognizes
targets via binding of C1q to immunoglobulin G or M, and the lectin
pathway, which recognizes glycans on the target surface via mannose-
binding lectin or ﬁcolins. Distinct from these is the alternative
pathway of complement, which is based on constant and sponta-
neous low-level activation in plasma. This results in a low number
of covalently bound (via hydroxyl or amine groups) C3b depositions
on practically all biological surfaces in contact with plasma,46,47 a
phenomenon that can be comparedwith blind shooting. The fate of the
C3b deposits determines whether the surface will be destroyed or not.
If the initial C3b deposit is rapidly inactivated, then activation fails to
proceed and the surface is spared.
However, if C3b is not rapidly eliminated or cleared from the
membrane surface, it participates in further formation of the C3 con-
vertase (C3bBb) that generates more C3b deposits, which in turn may
form similar enzymes leading to ampliﬁcation and ultimately elim-
ination of the target (Figure 2B).48
The special feature of the alternative pathway to spontaneously
attack any surface provides a strategy to defend against any kind of
biomaterial. This feature, however, leads to a potential to attack host
cells because some C3b is deposited onto self cells, too.49 Therefore,
all cells in contact with plasma without proper defenses are at risk
of destruction, making continuous and efﬁcient downregulation of
complement essential to self cells. If the regulation on host cells is com-
promised, as is often seen in aHUS and occasionally in other forms of
HUS, the ampliﬁed attack may rapidly cause cell and tissue damage.
Regulation of complement
The main complement regulators are the plasma protein factors H and
I and themembrane proteinsCD35,CD46,CD55, andCD59.50 Four of
the control proteins, factor H, CD35, CD46, andCD55, control C3b on
cell surfaces by acting as cofactors for factor I in proteolytic inactivation
of C3b, competing with factor B in binding to C3b, accelerating decay
of the formed C3bBb enzyme, or by amixture of these effects.51 These
proteins all contribute to the protection of endothelial cells; red blood
cells lack CD4652 and platelets lack CD35.53,54 CD59 acts later in the
cascade byblocking assembly of the lyticmembrane attack complex on
all plasma-exposed cells.
Studies on the pathogenesis of aHUS have revealed a central role of
factor H in discriminating between self cells and microbes (ie, whether
a target should be spared or destroyed).55,56 If factor H binds to
C3b deposited onto a surface, activation is efﬁciently inhibited. In the
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Figure 2. Consequences of complement activation.
(A) The complement system can be activated via
3 pathways: classical, lectin, and alternative. All path-
ways lead to formation of powerful enzymes, the C3-
convertases, followed by activation of the terminal
cascade. The main effector functions of complement
(promotion of opsonophagocytosis by opsonization
and chemotaxis and formation of lytic membrane
attack complexes) aim to destroy harmful agents such
as microbes. Lysis of target cells can lead to damage-
induced enhancement of complement activation. (B)
Alternative pathway activation is based on continuous,
low-level covalent deposition of C3b molecules onto
practically all surfaces in contact with plasma. If the
C3b molecule is allowed to form an enzyme (shown in
red), new C3b deposits will be formed around the
enzyme leading to rapid amplification of the activation.
If the regulator factor H binds to C3b, the convertase
enzyme is inactivated and no complement activation
follows. The simultaneous interaction of factor H with
both C3b and cell surface sialic acids (or possibly
glycosaminoglycans [GAGs]) is essential for proper
regulation on self red cells, platelets, and endothelial
cells. If this fails, disbalance between activation and
regulation may lead to pathogenesis of atypical HUS.
iC3b, C3b molecule incapable of forming an enzyme
with factor B.
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absence of factor H binding, activation proceeds (Figure 2B).57
Simultaneous binding of factor H to C3b and cell surface molecules
such as sialic acid or glycosaminoglycans is essential for efﬁcient
regulation of complement activation.55,58,59
Complement may cause cell damage in HUS
Mutations in complement proteins in aHUS
In STEC-HUS and secondary HUS, the disease process is usually
initiated by phenomena distinct from the complement system or linked
only indirectly to complement activation. In aHUS, however, com-
plement is centrally involved. In aHUS, mutations have been reported
in 5 central complement proteins. Most of these mutations lead to
impaired regulation of alternative pathway activation. Some disturb
recognition of C3b by factor H,56,60 factor I,61 or CD4662; some disturb
recognition of self-cell surface molecules, such as sialic acid or
glycosaminoglycans, by factor H.55,59 Some mutations in C3 or factor
B prolong the C3 convertase half-life or prevent its elimination.63,64
The frequencies of mutations observed in aHUS are shown in Table 1.
In addition, autoantibodies against factorHcan interferewith regulation
in a manner similar to mutations.69 The common feature for the muta-
tions and autoantibodies is impaired control of the complement al-
ternative pathway on self-cell surfaces.
Complement-mediated red cell and endothelial damage in HUS
Cells that are continuously exposed to complement alternative pathway
activation include all cells in contact with plasma: red cells, platelets,
leukocytes, and endothelial cells. The most vulnerable to rapid lysis
seem to be red cells, because they lack an efﬁcient membrane repair
system as observed in nucleated cells. However, some shedding of the
complement membrane attack complexes on these cells can occur,70
but contribution of this phenomenon to the protection of red cells from
complement lysis has not been proven. Complement attack against red
cells can rapidly lead to release of hemoglobin, as seen in paroxysmal
nocturnal hemoglobinuria (PNH).71
There are twomainmechanistic explanations underlying hemolysis
and the appearance of red cell fragments and schistocytes in the
peripheral blood in aHUS (ie, signs of microangiopathic hemolysis
characteristic for TMAs).72,73 The ﬁrst and traditional explanation is
mechanical hemolysis as a result of narrowedmicrovasculature caused
by microthrombi. However, narrowed capillaries have not been ex-
perimentally proven to lead to hemolysis or schistocytes in HUS.
One of the main problemswith this explanation is that deformability of
normal red cells is high, and channels narrower than 3 mm in diameter
do not allow passage of red cells at all.74 The second explanation,
complement-mediated lysis, is also possible either as a primary or
secondary cause, but the main challenge in this explanation is that
red cell fragments and schistocytes are not typical for complement-
mediated lysis in PNH.75 Thus, there may be alternative mechanisms
linked to stiffening of the red cell membrane by complement C3d (or
C3b) deposits.76,77 Further studies are needed to clarify the mechanism
for the clinically characteristic hemolysis in HUS cases associated with
complement regulation defects.
Endothelial cells and leukocytes can remove complement deposits
and membrane attack complexes more efﬁciently than red cells, either
by internalization or by shedding from the plasma membrane in
microvesicles.78,79 In addition, these cells may also repair membrane
damage. Endothelial cell damage is evident in histologic analysis of
biopsies taken from HUS patients during the acute stage.80 The reason
for endothelial cell damage in STEC-HUS is linked to Shiga toxin,
whereas damage in aHUS has been attributed to lytic or sublytic
complement attack.60,81 However, several other mechanisms affecting
endothelial cells can cause or contribute to the damage. Examples of
such factors are cell exposure to nitric oxide, free hemoglobin, activated
neutrophils and monocytes or released reactive oxygen species from
these cells,C3aorC5a,proinﬂammatory cytokines, proinﬂammatoryor
procoagulant microparticles, or cellular hypoxia due to microthrombi.
Cell damage–induced complement activation in HUS
Independent of the reason for the damage, injured endothelium may
activate the complement cascade.82 This activation may occur not
only via the alternative pathway but also (as observed in ischemia
reperfusion injury) by the classical and lectin pathways via exposure
of novel epitopes recognized by these pathways.83 In aHUS, the
alternative pathway is likely to be responsible for the damage, be-
cause the disease is associated with dysregulation of this pathway in
particular.8 The damage-induced enhancement of complement activa-
tion can lead to further damage of nearby cells, both the cells residing
in the immediate area and those passing by in the vicinity.84 It has
long been assumed that damage to endothelial cells is the ﬁrst step in
Table 1. Frequencies of the most common mutations identified in aHUS patients
Mutated gene/protein Type Frequency (%)*
Death or end-stage renal disease
3-10 y after onset (%)†
Factor H (including CFH/CFHR1 hybrid genes) Loss of complement regulation 24-28 70-80
MCP (CD46) Loss of complement regulation 5-9‡ ,20
Factor I Loss of complement regulation 4-8 60-70
C3 Gain of complement activation 2-8 60-70
Factor B Gain of complement activation 0-4 70
Thrombomodulin Possibly loss of complement regulation
and procoagulative state
0-5 50-60
CFHR1/3 deficiency with anti-factor H
autoantibodies
Loss of complement regulation 3-10§ 30-70
Diacylglycerol kinase e Prothrombotic 0-3|| 46
None identified 30-48 50
*Frequencies of the genetic abnormalities have been adopted from a recent review8 and cohort studies.65,66
†The values represent averages of the earlier reported values.10,90,65-67
‡Frequency of the isolated heterozygous MCP (CD46) mutation is usually 7% to 8%, but the mutations are frequently found in combination with other mutations in
complement genes (up to 22%).67
§Autoantibodies against factor H have been reported in 56% of pediatric aHUS cases in India.68
||Diacylglycerol kinase e mutations are most frequently found in patients with disease manifestation within the first year of life (5%-27% in this population).
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STEC-HUS and also in aHUS85,86; however, it is not known which
cells are damaged ﬁrst. Complement activation is also enhanced by
activation of platelets87 and hemoglobin (and heme) release from red
cells.88 Accordingly, in aHUS, simultaneous or even earlier damage of
these cells compared with that of endothelial cells is possible although
not proven.59
Platelets and coagulation in the pathogenesis
of HUS
Platelets in the pathogenesis of aHUS
Complement-mediated platelet activation has gained much less
attention in aHUS than hemolysis or endothelial cell damage. Platelets
may, however, be involved, either primarily or secondarily, in
pathogenesis of this disease because thrombocytopenia is a typical
feature of TMAs,89 and the thrombi in capillaries and arterioles contain
platelets90 in addition to red cells.91 Platelets are easily activated by
complement attack92 via the formation of membrane attack complex
on the platelet membrane,93 but some internalization or shedding of
the complement membrane attack complexes can occur.40 Although
platelets are normally protected from complement attack by the con-
certed action of factor H and membrane regulators,94 this protection
is impaired in aHUS.20 We have recently shown that protection of
platelets fromcomplement attackby factorH requires sialic acids on the
cell membrane in vitro.59 Therefore, impaired alternative pathway
regulation is a logical explanation for thrombocytopenia and could also
contribute to formation of platelet-rich microvascular thrombi.72,73
Links between complement, coagulation, and platelets in HUS
The common conclusion from the numerous studies linking comple-
ment and coagulation is that complement activation leads to initiation
or enhancement of coagulation. Complement can trigger coagulation
by 2 primary means. First, complement causes tissue damage via
formation of membrane attack complexes on endothelial cells. Second,
complement activation leads to release of C5a or formation of soluble
C5b-9 complexes that can induce endothelial cell activation and ex-
pression of procoagulative tissue factor.95-97 In addition, numerous
molecular interactions between complement and coagulation proteins
have been described.98,99 The physiological relevance of most of these
interactions has not been proven. Some interactions, such as cleavage
of C5 by thrombin, may be clinically relevant.100,101
There are also links between complement and platelets. The most
important of these seems to be the activation of platelets by membrane
attack complexes92 or C5a.102 The procoagulative effect of membrane
attack complexes seems to be mediated by platelet prothrombinase,103
not by irreversible cell damage.104 Independent of the reason for
the activation of platelets, it is well known that their activation and
aggregation is closely linked to coagulation, thereby creating another
bridgebetween activationof the complement and coagulation cascades.
In thepathogenesis of all 3 formsofHUS, formationofmicrothrombi in
capillaries and arterioles is central. The most important links between
complement activation, coagulation, and platelets in HUS are shown in
Figure 3.
Complement in disease processes and
therapy of HUS
Infections and complement activation
There are several reasons why infections are associated with HUS in
general: direct cell or tissue damage caused by a microbe, as seen
in STEC-HUS; indirect damage caused by complement activation
promoted by the pathogens105; infection-associated autoantibody
formation against factor H106; or possibly coagulation disorders during
infection.24 The acute phase reaction may also contribute, because
several complement proteins (at least C3, C1s, factor B, C5, C4, and
C1q107,108) are acute phase reactants. This provides an explanation for
the observed increase in complement hemolytic activity during the
acute phase.109 Increased plasma concentrations of these proteins do
not trigger complement activation as such but could promote activation
upon complement-activating circumstances caused by the microbe
itself or damaged host tissues.
Our recent study provided a novel possible explanation for why
certain infections can lead to secondary HUS. We observed that sialic
acid in in vitro assays is the main ligand for factor H on red cells and
also on platelets and endothelial cells.59 Pneumococci23 and inﬂuenza
A virus,24 most often seen in secondary HUS associated with infec-
tions, possess very active neuraminidases specialized in removing sialic
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Figure 3. Schematic presentation of the main links
between the complement and coagulation systems
and platelets in formation of microthrombi in
aHUS. Complement activation leads to release of the
C5a peptide, inducing tissue factor activity on endo-
thelial cells leading to a procoagulative state of the en-
dothelium. Activation of the coagulation cascade leads
to generation of active thrombin that is able to cleave
not only fibrinogen but also complement C5, which
thereby enables coagulation-enhanced complement
activation. Formation of membrane attack complexes
on endothelial cells and platelets can cause endothelial
cell damage and platelet activation. Finally, activation
of the coagulation system leads to platelet activation
via various mechanisms. Together, the coagulation sys-
tem and platelet activation/aggregation lead to formation
of microthrombi. The importance of complement in this
process in aHUS is clearly demonstrated by rapid in-
hibition of microvascular thrombosis by therapeutic com-
plement inhibition.
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acid from self cell surfaces.110,111 It is therefore possible that micro-
bial enzymes could make self blood cells more vulnerable to the
complement alternative pathway.112
Continuation of disease after removing the trigger
The course of STEC-HUS is usually self-limiting, although acute
kidney injury and systemic involvement can complicate and prolong
the disease. On the contrary, in some patientswith aHUS, or sometimes
secondary HUS, the acute disease continues after the trigger has been
removed. This is especially striking inpatientswhohave amutation in a
complement regulatory molecule for decades without symptoms but
fail to control the diseaseeven severalmonths after it hasbeen triggered.
All the provided explanations for this phenomenon are controversial.
One explanation is that complement attack against self cells during
the acute disease ﬂare leads to damage-induced ampliﬁcation of 1 or
more of the pathways, providing potential for longstanding comple-
ment activation. This is demonstrated by slow normalization of early
complement activation markers such as C3 fragments or factor B only
after several months of C5-blocking eculizumab therapy.113 Most
patients do not experience a relapse upon discontinuation of therapeutic
complement inhibition, although patients with factor Hmutations often
do.114,115 Another explanation for the longstanding disease process is
that endothelial cell activation continues for months after the rapid
termination of hemolysis and increase in platelet count.116
Therapeutic complement inhibition provides insight into
pathogenesis of HUS
The impact of complement activation on the pathogenesis of STEC-
HUS, aHUS, and secondary HUS seems to be variable, apparently
because of the biological phenomena linked to the pathogenesis.
The impact of complement is seenmost clearly in observing the effects
of therapeutic complement inhibition on these diseases. As expected,
complement inhibition is effective in patients who have a mutation in
complementmolecules or autoantibodies against factorH. The efﬁcacy
of therapeutic complement inhibition in patients with secondary HUS
has not been systematically assessed, but it has been shown to
be beneﬁcial in a number of patients who do not have a mutation in
any of the studied complement proteins.117 These include pa-
tients with autoimmunity (eg, scleroderma),118 systemic lupus
erythematosus,119,120 or catastrophic antiphospholipid syndrome121,122
and secondary HUS associated with postpartum period,123 HIV
infection,124 use of cytotoxic drugs,35 and either bone marrow or solid
organ transplantation.27,28 On the basis of these multiple single cases,
it seems that complement is involved in at least some patients with
secondary HUS. There is currently insufﬁcient evidence to classify
secondaryHUS into complement-driven and complement-independent
forms, but this might become a clinically relevant subclassiﬁcation
of secondary HUS in the future, as hinted at by some diagnostic
algorithms.15,125 From a clinical point of view, it already is important
and will probably be even more important in the future for making
justiﬁed decisions regarding which secondary HUS patients will need
expensive therapeutic complement inhibitors.
Althoughcomplement clearly contributes to diseasepathogenesis in
some patients with STEC-HUS,126 and some patients seem to beneﬁt
from early administration of eculizumab,127 most STEC-HUS patients
do not respond clearly to this drug.21 TTP is also not generally con-
sidered to be an indication for eculizumab treatment,128,129 mainly
because plasma therapy is usually effective. Despite this, eculizumab
has been beneﬁcial in some TTP cases that are refractory to con-
ventional therapy.130,131 Eculizumab does not seem to be effective for
the aHUS patients in whom a DGKe mutation is found10,113,132 or
in those with cobalamin C deﬁciency in adulthood133; however, this
treatment has been attempted in only a limited number of patients.
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Figure 4. A model of the parallel pathogenic
processes in HUS. Excess complement activation
on endothelial cell, platelet, and red cell surfaces leads
to C5a release and membrane attack complex (MAC)
formation. This leads to enhanced tissue factor (TF)
activity on the endothelium, activation and aggregation
of platelets, and release of hemoglobin and reduction
of nitric oxide (NO) in plasma. These phenomena lead
to a procoagulative state, coagulation, and thrombosis-
mediated tissue damage. There are several feedback
loops in this process. These loops can be seen as a
cycle that may be initiated at several points and where
several phenomena may take place in parallel. This
may explain why STEC-HUS, secondary HUS, and
aHUS share clinical features although the processes
start in various ways. DGKe, diacylglycerol kinase e.
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Multiple parallel processes leading to
clinically significant tissue damage
Parallel processes in pathogenesis of aHUS
The cellular or molecular consequences discussed above can be
summarized as parallel or consecutive phenomena with regard to the
various cells involved and the clinical signs typical forHUS and aHUS,
thereby forming amodel ofHUSpathogenesis (Figure 4). In thismodel,
the process is not linear but cyclical, and possibly all the processes
happen simultaneously in vivo. However, such a process may be ini-
tiated from different stages, resulting in a similar vicious cycle. The
primary point of process initiation could be in complement-mediated
cell damage, direct activation of platelets, initiation of a procoagulative
state in the endothelium, dysregulation of the coagulation or thrombo-
lytic pathways, or direct complement-independent cell damage.
Interplay between complement and thrombosis in other
thrombotic diseases
HUS and aHUS are not the only diseases in which thrombosis and
imbalance between complement activation and regulation are seen.
Accordingly, it may be relevant for clinical hematologists to have
insight into the role of complement in these diseases aswell. In some of
these diseases, such as PNH,134 sepsis syndrome,135 disseminated
intravascular coagulation,3 or ischemia-reperfusion injury,84 the alter-
native pathway contributes to or is even fully responsible for initiating
the complement activation. However, the pathologic defect leading to
these diseases may be independent of the alternative pathway. For
example, in PNH, the alternative pathway activation is responsible for
the physiological challenge of blood cells with C3b; this leads to cell
damage only because of the absence of glycophosphoinositol-anchored
complement regulators CD55 and CD59.134 In some others, such as
catastrophic antiphospholipid antibody syndrome, antibody-mediated
rejection, or scleroderma renal crisis, the classical pathway is putatively
mostly responsible for complement overactivation, although the other
complement pathways may also contribute.
The common feature for the clinically different thrombotic diseases
with complement activation could be a vicious cycle. Such a cycle could
be formed between complement-mediated cell damage (to endothelial
cells, platelets, and red cells), formation of ﬁbrin or platelet thrombi
(or both), tissue hypoxia as a result of vascular occlusion, further
tissue damage, and damage-induced secondary complement over-
activation (Figure 5). Most of the links in this kind of self-amplifying
process are evident, but the clinical importance of some others in
human diseases remains to be shown. The use of therapeutic comple-
ment inhibition beyond the current indications of eculizumab (aHUS
and PNH) might demonstrate the relevance of complement in at least
some of these disease processes.
Conclusions
Complement activation is central in the pathogenesis of aHUS.
Complement activation may also contribute to pathogenesis in some
patients with STEC-HUS and secondary HUS, either by regulation
defects or by triggers that lead to enhanced complement activation.
STEC-HUS is associated with a gastrointestinal infection with STEC,
and secondary HUS is associated with a coexisting disease, whereas
aHUS is usually associated with complement dysregulation leading to
attack against all cells in contact with plasma. The typical clinical triad
of microangiopathic hemolytic anemia, thrombocytopenia, and organ
damage can be explained in STEC-HUS by the cytotoxic effects of
Shiga toxin and in secondaryHUS and aHUSusually by complement-
mediated processes.
It is logical that therapeutic complement inhibition is effective in
aHUS. The impact of complement in the pathogenesis of STEC-HUS
and secondary HUS is still uncertain. Nevertheless, at least some
patients seem to beneﬁt from therapeutic complement inhibition,
indicating that complement may also be involved in these diseases.
In the pathogenesis of aHUS, STEC-HUS, and at least some forms
of secondary HUS, the interplay between complement, coagulation,
and platelets seems to be essential. The primary point of process
initiation could be either complement-mediated or not. Independent
of the initiation point, the process may have similar features because of
numerous feedback loops and powerful ampliﬁcation under certain
conditions. In general, it is likely that HUS and aHUS are not the only
diseases in which the feedback loop among cell damage, coagulation
and thrombosis, hypoxia-mediated endothelial activation, and activation
C5a-mediated inflammation
and MAC pores
Alternative
pathway
Activation of complement
on self surfaces:
Classical
pathway
aHUS
PNH
Sepsis and DIC
Ischemia-reperfusion injury
CAPS
Antibody-mediated
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Damage to endothelium and blood cells Coagulation and thrombosis
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Figure 5. Schematic model of the role of comple-
ment activation, cell damage, and thrombosis in
various severe diseases or conditions with major
thrombotic problems. Activation of complement can
occur via the alternative pathway (in the absence
of antibodies) or the classical pathway (in the presence
of target-bound antibodies). In each of the indicated
diseases or conditions, endothelium, red cells, or platelets
are damaged. This may contribute to coagulation and
thrombosis, and direct procoagulative effects may also
participate (red arrows). Thrombosis can lead to further
tissue damage and increasing complement activation.
The process can enhance itself via positive feedback
loops and form a vicious cycle. Although complement is
involved in each of these diseases, its impact needs to be
clarified in clinical studies. CAPS, catastrophic antiphos-
pholipid syndrome, DIC, disseminated intravascular co-
agulation; PLG, plasminogen; THBD, thrombomodulin.
BLOOD, 25 MAY 2017 x VOLUME 129, NUMBER 21 HUS AND ATYPICAL HUS 2853
For personal use only.on June 13, 2017. by guest  www.bloodjournal.orgFrom 
of complement form a vicious cycle. Therefore, therapeutic comple-
ment inhibition may prove to be beneﬁcial for a number of systemic
thrombotic diseases in the future.
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